These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 34332341)
1. Subtyping of head and neck squamous cell cancers based on immune signatures. Song D; Lyu H; Feng Q; Luo J; Li L; Wang X Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341 [TBL] [Abstract][Full Text] [Related]
2. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma. Liu Q; Nie R; Li M; Li L; Zhou H; Lu H; Wang X Comput Struct Biotechnol J; 2021; 19():4472-4485. PubMed ID: 34471493 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557 [TBL] [Abstract][Full Text] [Related]
4. Gene set enrichment analysis identifies immune subtypes of kidney renal clear cell carcinoma with significantly different molecular and clinical properties. Chen Z; Cao W; Luo J; Abdelrahman Z; Lu Q; Wang H; Wang X Front Immunol; 2023; 14():1191365. PubMed ID: 37426638 [TBL] [Abstract][Full Text] [Related]
5. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma. Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115 [TBL] [Abstract][Full Text] [Related]
6. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma. Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553 [TBL] [Abstract][Full Text] [Related]
7. Constructing heterogeneous single-cell landscape and identifying microenvironment molecular characteristics of primary and lymphatic metastatic head and neck squamous cell carcinoma. Zhang J; Liu Y; Xia L; Zhen J; Gao J; Atsushi T Comput Biol Med; 2023 Oct; 165():107459. PubMed ID: 37713790 [TBL] [Abstract][Full Text] [Related]
8. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791 [No Abstract] [Full Text] [Related]
9. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma. Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580 [TBL] [Abstract][Full Text] [Related]
10. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205 [TBL] [Abstract][Full Text] [Related]
11. Correlate the Lyu H; Li M; Jiang Z; Liu Z; Wang X Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295 [TBL] [Abstract][Full Text] [Related]
12. Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients. Sacconi A; Muti P; Pulito C; Urbani G; Allegretti M; Pellini R; Mehterov N; Ben-David U; Strano S; Bossi P; Blandino G Mol Cancer; 2023 Nov; 22(1):192. PubMed ID: 38031025 [TBL] [Abstract][Full Text] [Related]
13. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509 [TBL] [Abstract][Full Text] [Related]
14. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer. Cao H; Lan T; Kuang S; Wang L; Li J; Li Q; Li Y; Xu Q; Chen Q; Ren S; Lan C; Ouyang N; Liao J; Huang Y; Li J Drug Resist Updat; 2024 Sep; 76():101095. PubMed ID: 38986165 [TBL] [Abstract][Full Text] [Related]
15. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268 [TBL] [Abstract][Full Text] [Related]
16. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses. Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX Front Immunol; 2021; 12():791621. PubMed ID: 35003112 [TBL] [Abstract][Full Text] [Related]
17. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis. Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727 [TBL] [Abstract][Full Text] [Related]
19. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status. Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731 [TBL] [Abstract][Full Text] [Related]
20. Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma. Zhu C; Gu L; Liu Z; Li J; Yao M; Fang C BMC Cancer; 2021 Jul; 21(1):836. PubMed ID: 34284746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]